China Resources Jiangzhong Pharmaceutical Co.,Ltd (SHA:600750)
China · Delayed Price · Currency is CNY 25.16
+0.50 (2.03%)
Feb 3, 2026, 2:55 PM CST
SHA:600750 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,207 | 4,404 | 4,527 | 3,846 | 2,856 | 2,435 |
Other Revenue | 31.51 | 31.51 | 26.23 | 39.58 | 17.88 | 6.9 |
| 4,239 | 4,435 | 4,553 | 3,885 | 2,874 | 2,441 | |
Revenue Growth (YoY) | -4.66% | -2.59% | 17.19% | 35.19% | 17.72% | -0.33% |
Cost of Revenue | 1,552 | 1,634 | 1,648 | 1,384 | 1,026 | 847.82 |
Gross Profit | 2,687 | 2,801 | 2,906 | 2,501 | 1,848 | 1,594 |
Selling, General & Admin | 1,534 | 1,724 | 1,862 | 1,713 | 1,196 | 962.24 |
Research & Development | 143.8 | 130.43 | 141.42 | 99.97 | 87.82 | 55.55 |
Other Operating Expenses | 11.95 | 41.58 | 55.35 | 59.31 | 52.48 | 45.71 |
Operating Expenses | 1,718 | 1,904 | 2,058 | 1,874 | 1,336 | 1,065 |
Operating Income | 968.81 | 897.39 | 847.35 | 626.7 | 511.29 | 528.48 |
Interest Expense | -2.15 | -1.71 | -6.98 | -4.38 | -3.46 | -1.93 |
Interest & Investment Income | 74.49 | 77.48 | 68.79 | 37 | 26.3 | 15.27 |
Other Non Operating Income (Expenses) | 20.97 | 22.09 | -2.29 | -12.33 | -8.77 | -0.06 |
EBT Excluding Unusual Items | 1,062 | 995.25 | 906.87 | 646.99 | 525.36 | 541.75 |
Gain (Loss) on Sale of Investments | -12.12 | -11.46 | -40.05 | 57.1 | 51.25 | -15.85 |
Gain (Loss) on Sale of Assets | 2.72 | 1.84 | 1.22 | -0.13 | 0.9 | -0.21 |
Asset Writedown | 26.63 | -1.05 | -2.04 | - | - | - |
Other Unusual Items | 46.32 | 41.03 | 50.12 | 49.32 | 45.63 | 53.7 |
Pretax Income | 1,126 | 1,026 | 916.12 | 753.28 | 623.14 | 579.4 |
Income Tax Expense | 223.03 | 165.11 | 129.11 | 106.89 | 92.19 | 89.07 |
Earnings From Continuing Operations | 902.65 | 860.51 | 787.01 | 646.39 | 530.95 | 490.32 |
Net Income to Company | 902.65 | 860.51 | 787.01 | 646.39 | 530.95 | 490.32 |
Minority Interest in Earnings | -78.57 | -72.31 | -68.34 | -48.15 | -25.26 | -16.58 |
Net Income | 824.08 | 788.19 | 718.67 | 598.24 | 505.69 | 473.74 |
Net Income to Common | 824.08 | 788.19 | 718.67 | 598.24 | 505.69 | 473.74 |
Net Income Growth | 6.48% | 9.67% | 20.13% | 18.30% | 6.74% | 2.19% |
Shares Outstanding (Basic) | 634 | 631 | 719 | 630 | 632 | 632 |
Shares Outstanding (Diluted) | 634 | 631 | 719 | 630 | 632 | 632 |
Shares Change (YoY) | -11.70% | -12.26% | 14.12% | -0.38% | 0.07% | 0.83% |
EPS (Basic) | 1.30 | 1.25 | 1.00 | 0.95 | 0.80 | 0.75 |
EPS (Diluted) | 1.30 | 1.25 | 1.00 | 0.95 | 0.80 | 0.75 |
EPS Growth | 20.59% | 25.00% | 5.26% | 18.75% | 6.67% | 1.35% |
Free Cash Flow | 954.14 | 495.49 | 828.31 | 676.02 | 728.55 | 569.97 |
Free Cash Flow Per Share | 1.51 | 0.79 | 1.15 | 1.07 | 1.15 | 0.90 |
Dividend Per Share | 1.200 | 1.200 | 1.300 | 1.150 | 0.650 | 0.270 |
Dividend Growth | - | -7.69% | 13.04% | 76.92% | 140.74% | 8.00% |
Gross Margin | 63.40% | 63.16% | 63.81% | 64.37% | 64.29% | 65.27% |
Operating Margin | 22.86% | 20.23% | 18.61% | 16.13% | 17.79% | 21.65% |
Profit Margin | 19.44% | 17.77% | 15.78% | 15.40% | 17.59% | 19.40% |
Free Cash Flow Margin | 22.51% | 11.17% | 18.19% | 17.40% | 25.35% | 23.34% |
EBITDA | 1,109 | 1,031 | 971.28 | 746.78 | 626.2 | 641.24 |
EBITDA Margin | 26.16% | 23.24% | 21.33% | 19.22% | 21.79% | 26.27% |
D&A For EBITDA | 140.21 | 133.24 | 123.94 | 120.08 | 114.91 | 112.77 |
EBIT | 968.81 | 897.39 | 847.35 | 626.7 | 511.29 | 528.48 |
EBIT Margin | 22.86% | 20.23% | 18.61% | 16.13% | 17.79% | 21.65% |
Effective Tax Rate | 19.81% | 16.10% | 14.09% | 14.19% | 14.79% | 15.37% |
Revenue as Reported | 4,239 | 4,435 | 4,553 | 3,885 | 2,874 | 2,441 |
Advertising Expenses | - | 364.67 | 404.92 | 318.77 | 321.22 | 255.89 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.